secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2024-03-19T23:59:59+00:00
Accession:  0001437749-24-008508
Event type: litigation
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma partially dismissed as plaintiff in Tagrisso patent suit; trial set May 13
-------------------------------------------------------------------------------

- Court denied AstraZeneca's motions for patent invalidity and summary judgment of non-infringement.
- AstraZeneca's motion to dismiss Puma as plaintiff granted on standing grounds; Puma remains counterclaim-defendant.
- Puma retains contractual rights under Pfizer license to seek monetary damages in the case.
- Jury trial scheduled for May 13, 2024 in Delaware federal court.
- Suit alleges Tagrisso infringes patents licensed exclusively to Puma; Wyeth continues as co-plaintiff.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774924008508/0001437749-24-008508-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774924008508/pbyi20240319_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-008508

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer